Evidence map›Paper›PMID 26062933›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2015

Biodistribution of the ¹⁸F-FPPRGD₂ PET radiopharmaceutical in cancer patients: an atlas of SUV measurements.

Ryogo Minamimoto, Mehran Jamali, Amir Barkhodari, Camila Mosci, Erik Mittra, Bin Shen, Frederick Chin, Sanjiv Sam Gambhir, Andrei Iagaru

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01806675 (Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis), which is not on this map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01806675 phase1 / phase2completednot on this map

Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis

TypeinterventionalSponsorSanjiv Sam GambhirRan2013 to 2019Enrolled25ConditionsAdult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast CancerArms18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 44 citations in OpenAlex.

  1. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018
    Trial
  2. Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer.European journal of nuclear medicine and molecular imaging · 2016
    Trial
  3. Review
  4. Review
  5. Comparison of integrin αEuropean journal of hybrid imaging · 2023
    Article
  6. Article
  7. Review
  8. Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas.European journal of nuclear medicine and molecular imaging · 2021
    Review
  9. Review
  10. Review
  11. Article
  12. Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [European journal of nuclear medicine and molecular imaging · 2020
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Imaging angiogenesis usingJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2017
    Article
  20. Inter-heterogeneity and intra-heterogeneity of αEuropean journal of nuclear medicine and molecular imaging · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ryogo MinamimotoDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA 300 Pasteur Drive, C21, Stanford, CA, 94305-5281, USA. ryogom@stanford.edu.
Mehran JamaliDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA 300 Pasteur Drive, C21, Stanford, CA, 94305-5281, USA.
Amir BarkhodariDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA 300 Pasteur Drive, C21, Stanford, CA, 94305-5281, USA.
Camila MosciDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA 300 Pasteur Drive, C21, Stanford, CA, 94305-5281, USA.
Erik MittraDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA 300 Pasteur Drive, C21, Stanford, CA, 94305-5281, USA.
Bin ShenMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, USA.
Frederick ChinMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, USA.
Sanjiv Sam GambhirDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA 300 Pasteur Drive, C21, Stanford, CA, 94305-5281, USA.
Andrei IagaruDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA 300 Pasteur Drive, C21, Stanford, CA, 94305-5281, USA. aiagaru@stanford.edu.
Stanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to investigate the biodistribution of 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) ((18)F-FPPRGD2) in cancer patients and to compare its uptake in malignant lesions with (18)F-FDG uptake.

methodsA total of 35 patients (11 men, 24 women, mean age 52.1 ± 10.8 years) were enrolled prospectively and had (18)F-FPPRGD2 PET/CT prior to treatment. Maximum standardized uptake values (SUVmax) and mean SUV (SUVmean) were measured in 23 normal tissues in each patient, as well as in known or suspected cancer lesions. Differences between (18)F-FPPRGD2 uptake and (18)F-FDG uptake were also evaluated in 28 of the 35 patients.

resultsAreas of high (18)F-FPPRGD2 accumulation (SUVmax range 8.9 - 94.4, SUVmean range 7.1 - 64.4) included the bladder and kidneys. Moderate uptake (SUVmax range 2.1 - 6.3, SUVmean range 1.1 - 4.5) was found in the choroid plexus, salivary glands, thyroid, liver, spleen, pancreas, small bowel and skeleton. Compared with (18)F-FDG, (18)F-FPPRGD2 showed higher tumor-to-background ratio in brain lesions (13.4 ± 8.5 vs. 1.1 ± 0.5, P < 0.001), but no significant difference in body lesions (3.2 ± 1.9 vs. 4.4 ± 4.2, P = 0.10). There was no significant correlation between the uptake values (SUVmax and SUVmean) for (18)F FPPRGD2 and those for (18)F-FDG.

conclusionThe biodistribution of (18)F-FPPRGD2 in cancer patients is similar to that of other RGD dimer peptides and it is suitable for clinical use. The lack of significant correlation between (18)F-FPPRGD2 and (18)F-FDG uptake confirms that the information provided by each PET tracer is different.

Indexed as

Positron-Emission TomographyBiological TransportFemaleHumansMaleMiddle AgedNeoplasmsOligopeptidesPeptides, CyclicRadiopharmaceuticalsTissue Distributionarginyl-glycyl-aspartic acidFPP(RGD)2OligopeptidesPeptides, CyclicRadiopharmaceuticals18F-FPPRGD2 PET/CTAngiogenesisAtlasPET/CTαvβ3 integrin expression

Identifiers

PMID26062933
OpenAlexW2469306941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.